Carotid stenting has become the “procedure du jour”; however, multiple studies and articles tout both its advantages and failures. With the rapid advancement and public acceptance of catheter-based technology, expansion into the realm of carotid revascularization was just a matter of time. The initial justification for CAS was based on the results of multiple randomized trials (the NASCET, ECST, ACAS, and ACST) that evaluated CEA with BMT. Patients who were excluded from the CEA trials as “high risk” may possibly benefit from CAS.
Bush RL. To Stent or Not to Stent: The Question Remains Unanswered: Comment on “Secondary Stroke Prevention in the Era of Carotid Stenting”. Arch Surg. 2010;145(10):935. doi:10.1001/archsurg.2010.192
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.